Lung cancer is the leading cause of cancer-related death in South Africa, and it is also one of the most expensive conditions in the private healthcare system. Treatment costs can reach hundreds of thousands of rands per year — yet what your medical aid is required to fund, versus what it is merely expected to fund, is widely misunderstood. This article breaks down the coverage reality for South African medical aid members.
What Is Lung Cancer?
Lung cancer originates in the cells lining the airways or lung tissue. It is classified into two main biological types:
- Non-small cell lung cancer (NSCLC) — approximately 85% of all cases. Further subdivided into adenocarcinoma (most common, often with targetable mutations), squamous cell carcinoma, and large cell carcinoma.
- Small cell lung cancer (SCLC) — approximately 15% of cases; more aggressive, almost always driven by smoking, and staged as limited or extensive disease.
This distinction matters enormously for treatment and for medical aid cover decisions. NSCLC with certain molecular markers (EGFR mutation, ALK rearrangement, ROS1, KRAS G12C, PD-L1 high expression) qualifies for targeted therapies and immunotherapy — but many of these are not classified as PMB minimum treatment and require exceptional-needs authorisation.
How Common Is Lung Cancer in South Africa?
The National Cancer Registry (NCR) consistently lists lung cancer among the top cancers by mortality for both men and women. South Africa has an adult smoking prevalence of approximately 22–26%, far higher than global targets. There is also a significant secondhand smoke burden, and occupational exposures (asbestos in mining and construction) contribute to cases in non-smokers.
In the private healthcare sector, lung cancer is a major driver of oncology sub-limit exhaustion. Unlike some other cancers, many lung cancer patients are diagnosed at an advanced stage, where treatment is palliative (extending life) rather than curative — meaning treatment costs accrue continuously, year after year.
Is Lung Cancer a PMB Condition?
Yes. Lung cancer is covered under the Prescribed Minimum Benefits (PMB) framework as a Level 1 oncological condition under the Diagnosis and Treatment Pairs (DTP) schedule. All registered South African medical schemes are legally required to fund:
- Diagnosis: Bronchoscopy, CT-guided biopsy, PET/CT staging, pathology.
- Surgery: Lobectomy, pneumonectomy, wedge resection where indicated (Stage I–II and selected Stage III).
- Radiation therapy: External beam radiation, stereotactic body radiation therapy (SBRT) for early-stage inoperable disease.
- Standard chemotherapy: Platinum-based doublets (cisplatin/pemetrexed for adenocarcinoma; cisplatin/etoposide for SCLC; carboplatin combinations).
What the PMB does not guarantee: - Targeted therapies (osimertinib/Tagrisso for EGFR+; alectinib/Alecensa for ALK+; sotorasib for KRAS G12C) — these are generally not the PMB minimum treatment standard and require exceptional-needs motivation. - Immunotherapy (pembrolizumab/Keytruda; nivolumab/Opdivo; atezolizumab/Tecentriq) — typically exceptional-needs regardless of PD-L1 status. - Maintenance therapy after first-line chemotherapy.
The difference between PMB platinum-doublet chemotherapy (~R30,000–R40,000/cycle) and targeted therapies like osimertinib (~R40,000–R65,000/month) represents tens of thousands of rands per month — and most of that difference sits on the patient if exceptional-needs authorisation is denied.
How Does Medical Aid Cover Lung Cancer?
What schemes must fund (PMB minimum):
| Treatment | PMB Status | Notes |
|---|---|---|
| Diagnosis: CT, PET/CT, bronchoscopy, biopsy | Yes | At DSP rates |
| Molecular testing (EGFR, ALK, ROS1, KRAS, PD-L1) | Varies | Critical for treatment selection; funding inconsistent across schemes |
| Surgery (lobectomy/pneumonectomy) | Yes | At DSP rates |
| Radiation therapy | Yes | PMB minimum standard |
| Platinum-based chemotherapy | Yes | PMB minimum standard |
| Osimertinib (EGFR+) | No — exceptional needs | Must motivate with genotyping result |
| Alectinib (ALK+) | No — exceptional needs | Must motivate with ALK FISH/IHC result |
| Pembrolizumab (high PD-L1) | No — exceptional needs | Even at PD-L1 ≥50%, most SA schemes require motivation |
| Pemetrexed maintenance | Usually exceptional needs |
The molecular testing gap: Your scheme must fund your diagnosis, but whether it funds the molecular tests that determine whether targeted therapy is appropriate is inconsistently applied. Without EGFR, ALK, and PD-L1 testing, your oncologist cannot prescribe targeted therapy or immunotherapy. If your scheme does not fund these tests, you will need to pay out of pocket — costs range from R3,000 to R12,000 per test panel. Do not skip these tests; the results directly determine your treatment protocol.
Day-to-Day Costs: What to Budget For
Lung cancer management involves ongoing specialist costs beyond hospitalisation:
- Pulmonologist or thoracic oncologist consultation: R1,400–R2,800 per visit
- Medical oncologist consultation: R1,400–R2,800 per visit (ongoing, monthly or per-cycle)
- CT surveillance scans: R4,000–R8,000 each (typically 3-monthly while on treatment)
- Platinum-based chemotherapy (hospital infusion): R30,000–R60,000 per cycle × 4–6 cycles
- Targeted therapy (osimertinib, alectinib) — if approved: R40,000–R65,000/month ongoing
- Immunotherapy (pembrolizumab) — if approved: R45,000–R70,000 per 3-week infusion cycle
Estimated annual cost ranges:
| Scenario | Estimated Annual Cost |
|---|---|
| Stage I–II, surgery ± radiation (curative) | R60,000 – R200,000 |
| Stage III, chemoradiation (curative intent) | R150,000 – R300,000 |
| Stage IV, platinum doublet chemotherapy | R150,000 – R350,000 |
| Stage IV EGFR+, osimertinib (targeted) | R450,000 – R800,000+ |
| Stage IV, pembrolizumab (immunotherapy) | R500,000 – R850,000+ |
These estimates include specialist fees and imaging. They do not account for gap cover shortfalls.
Gap Cover Relevance
Gap cover is relevant for lung cancer. Shortfalls arise at multiple points:
- Thoracic surgeon: Lobectomy and pneumonectomy attract significant shortfalls (R20,000–R60,000 per procedure above scheme tariff).
- Medical oncologist infusion fees: Specialists bill at 200–400% of medical aid tariff per infusion visit.
- Radiation oncologist: SBRT planning and delivery generates shortfalls.
- Anaesthesiologist: At each surgical event.
- Radiologist: PET/CT interpretation.
For a patient receiving surgical resection followed by chemotherapy, total annual shortfalls can reach R80,000–R180,000. Gap cover's Overall Payment Limit (OPL) of approximately R220,000/year provides meaningful protection. For advanced-stage patients on continuous targeted therapy or immunotherapy infusions, the OPL may be reached before year-end.
Gap cover does not cover the cost of medicines themselves — it covers provider shortfalls on procedures and consultations. The medication costs for targeted therapy and immunotherapy are separate, and whether they are funded depends entirely on your scheme's exceptional-needs outcome.
Key Questions to Ask Your Scheme
- Is my molecular testing funded? "Will the scheme fund EGFR, ALK, ROS1, KRAS G12C, and PD-L1 testing as part of my PMB diagnostic workup?"
- What is my oncology sub-limit? Ask for the exact rand amount, and whether PMB treatment is subject to or exempt from this limit.
- What is the exceptional-needs process? "How do I apply for targeted therapy or immunotherapy, and what is the typical turnaround time?"
- Which hospitals are in my DSP network? Surgery and radiation at a non-DSP facility may result in a co-payment.
- Does my plan include a dedicated oncology case manager? Case management significantly improves authorisation outcomes and claim accuracy.
Talk to Eldon
Not sure if your plan covers lung cancer treatment adequately? AURA analyses 112 plans across 7 schemes — including oncology sub-limits, exceptional-needs track records, and DSP networks — to find the plan that actually matches your needs.
See which plans pay for lung cancer cover →